News | Heart Valve Technology | September 19, 2016

Boston Scientific Gains European Approval for Next Generation Lotus Edge TAVR System

System has a feature to help reduce need for pacemakers

Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge system in its deployed position. The Lotus valve expands outward as it is compressed and buckled in the deployment position. It also has a skirt to help eliminate paravalvular leaks.

Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge deployment catheter.

September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the company's next generation transcatheter aortic valve replacement (TAVR) technology. The Lotus Edge valve system is indicated for aortic valve replacement in patients with severe aortic stenosis who are considered at high risk for surgical valve replacement. Instead of open heart surgery, the replacement valve is delivered via transcatheter percutaneous delivery, a minimally invasive procedure involving a small incision to gain access to a blood vessel.

 
In comparison to the Lotus Valve System, this next iteration incorporates a more flexible, lower profile catheter designed to improve ease of use and accommodate tortuous anatomy. Another differentiating feature of the Lotus Edge valve system is the inclusion of Depth Guard, a design element intended to reduce the need for a permanent pacemaker (PPM). 
 
"The Lotus Edge device is a highly anticipated next generation of the Lotus Valve System," said Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. "It retains many of its predecessor's unique and valuable proprietary features, including the ability to reposition the device precisely and prevent paravalvular leak, while incorporating new design characteristics such as a more flexible catheter for easier delivery and Depth Guard technology designed to reduce valve interaction with the conduction system of the heart during valve deployment."
 
Leveraging the current Lotus platform, the Lotus Edge valve system integrates the Adaptive Seal technology which minimizes paravalvular leak regurgitation or PVL, as demonstrated in the 1,000 patient RESPOND Post-Market Registry. This study found that 91.9 percent of patients had core-lab adjudicated trace or no PVL pre-discharge, and 7.7 percent had mild PVL. No patients had severe PVL and only 0.3 percent of patients had moderate PVL. Lotus Edge continues to be the only TAVR device that offers controlled mechanical expansion, which allows the valve to be fully deployed and assessed and then repositioned or fully retrieved by the physician, if needed.

Read the article “Boston Scientific Lotus Valve System Demonstrates Extremely Low PVL Rates.”

The Lotus Edge valve system will be available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. The Lotus Valve System is an investigational device in the United States and Japan and is not available for sale in those countries.

  

Read the related article, “Advances and Future Directions for Transcatheter Valves.”
 

For more information: www.bostonscientific.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init